The superstars of precision medicine—EGFR inhibitors in adjuvant treatment of lung cancer

Podobne zapisy

• Treatment failure patterns of adjuvant gefitinib therapy and minimal residual disease detection in resected EGFR-mutant non-small cell lung cancer: author’s reply
  od: Xu, Song-Tao, i wsp.
  Wydane: (2020)
• Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer
  od: Zhai, Haoran, i wsp.
  Wydane: (2015)
• The resistance mechanisms and treatment strategies for EGFR-mutant advanced non-small-cell lung cancer
  od: Zhong, Wen-Zhao, i wsp.
  Wydane: (2017)
• EGFR Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas
  od: Chen, Zhi-Yong, i wsp.
  Wydane: (2012)
• Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer
  od: Yap, Timothy A, i wsp.
  Wydane: (2014)